Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furaprevir + Peg-IFN + Ribavirin in HCV GT1b
NCT02340962Phase 2Completed
- Sponsor
- TaiGen Biotechnology Co., Ltd.
- Start
- May 2015
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of furaprevir in hepatitis C (HCV), sponsored by TaiGen Biotechnology Co., Ltd.. Started May 2015; status: completed.
02
Drugs
furaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02340962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02340962.